Discovery of Benzo[ d ]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway
Journal of Medicinal Chemistry · 24.10.2024 · 67 (20) · 18526-18548
DOI: 10.1021/acs.jmedchem.4c01899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.10.2024. Verfasst von Kaizhen Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, B7-H1 Antigen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Jiangsu Funding Program for Excellent Postdoctoral Talent.
Abstract (Originalsprache)
The blockers of programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway have achieved great clinical success. However, the limited efficacy and low tumor response rate of anti-PD-1/PD-L1 monotherapy limit the clinical application of PD-1/PD-L1 inhibitors. V-domain immunoglobulin suppressor of T-cell activation (VISTA), a novel checkpoint regulator, exhibits potential synergy with PD-1/PD-L1 in enhancing antitumor immunity. Herein, we report the discovery of benzo[d]oxazole B3 as novel dual small-molecule inhibitors targeting PD-1/PD-L1 and VISTA with high PD-1/PD-L1 inhibitory activity and VISTA binding affinity. B3 rescues the immunosuppression of T-cells mediated by PD-L1 and VISTA and activates antitumor immunity effectively. Moreover, B3 could induce degradation of PD-L1 and VISTA in tumor cell. Furthermore, B3 displays significant in vivo antitumor efficacy in a CT26 mouse model. Our results discover B3 as a promising dual PD-1/PD-L1 and VISTA inhibitor, providing a novel therapeutic strategy to overcome the limitations of current anti-PD-1/PD-L1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- Innovation Department of the Research Institute, Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing 210046, China.
ORCID-Profile: Kuojun Zhang, Xiangyu Zhang, Tianyu Wang
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Jiangsu Funding Program for Excellent Postdoctoral Talent
Zitieren
APA
Wang, K., Cai, S., Cheng, Y., Qi, Z., Ni, X., Zhang, K., Xiao, Y., Zhang, X., & Wang, T. (2024). Discovery of Benzo[ d ]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway. Journal of Medicinal Chemistry, 67(20), 18526-18548. https://doi.org/10.1021/acs.jmedchem.4c01899
Vancouver
Wang K, Cai S, Cheng Y, Qi Z, Ni X, Zhang K, et al. Discovery of Benzo[ d ]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway. Journal of Medicinal Chemistry. 2024;67(20):18526-18548. doi:10.1021/acs.jmedchem.4c01899
BibTeX
@article{Wang2024,
author = {Wang, Kaizhen and Cai, Shi and Cheng, Yao and Qi, Zhihao and Ni, Xiang and Zhang, Kuojun and Xiao, Yibei and Zhang, Xiangyu and Wang, Tianyu},
title = {Discovery of Benzo[ d ]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {20},
pages = {18526--18548},
doi = {10.1021/acs.jmedchem.4c01899}
}
EUVIMED